ATS 2019 Virtual Final Program

treatment of OSA is continuous positive airway pressure (CPAP), which reduces daytime sleepiness and improves quality of life in symptomatic patients. However, the majority of individuals with OSA do not report symptoms, and adherence to CPAP is poor. This course will examine: 1) the pathophysiological effects of OSA on metabolic disorders and CVD, 2) the evidence linking OSA to metabolic disorders and CVD, 3) the implementation of the results of the clinical trials into practice in this area. Each talk will start with one or two cases with questions on management, and the attendees will be asked to press the right choice on the display. All questions will be answered again and discussed at one of the final sessions before the course evaluation. Chairing: S.S. Redline, MD, MPH, Boston, MA S. Javaheri, MD, Cincinnati, OH 8:00 Introduction S. Javaheri, MD, Cincinnati, OH 8:10 Associations Between OSA and Cardiovascular Risk Factors Across Populations S.S. Redline, MD, MPH, Boston, MA 8:40 Cardiovascular Mechanisms in OSA and Response to Treatment B. Prasad, MD, Chicago, IL 9:10 Oxidative Stress, Inflammation in OSA and Response to Treatment S. Ryan, MD, PhD, Dublin, Ireland 9:40 Interactions Between OSA, Obesity, Metabolic Syndrome, Hyperlipidemia, and Response to Treatment S. Pamidi, MD, Montreal, Canada 10:10 Break 10:30 Association Between OSA and Diabetes Mellitus, and Response to Treatment E. Tasali, MD, Chicago, IL 11:00 Association Between OSA and Hypertension, and Response to Treatment J. Pepin, MD, PhD, Grenoble, France 11:30 Association Between OSA and Cardiac Failure, and Response to Treatment S. Javaheri, MD, Cincinnati, OH 12:00 LUNCH 1:00 Association Between OSA and Cardiac Arrhythmia, and Response to Treatment R. Mehra, MD, Cleveland, OH 1:30 Association Between OSA and Coronary Artery Disease, and Response to Treatment Y. Peker, MD, PhD, Istanbul, Turkey 2:00 Association Between OSA and Stroke, and Response to Treatment K. Yaggi, MD, New Haven, CT 2:30 Break 2:50 Lessons from the SAVE Trial: Future Perspectives R.D. McEvoy, MD, Adelaide, Australia 3:20 Interactive Panel Discussion: Applying the Literature to Clinical Cases L.F. Drager, MD, Sao Paulo, Brazil 3:50 Summary and Course Evaluation S.S. Redline, MD, MPH, Boston, MA BASIC • CLINICAL POSTGRADUATE COURSE CME Credits Available: 6.75 PG12 STATE OF THE ART: LUNG CANCER 2019 R Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 : Registrants must bring a laptop to the course to view the course material. Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems; Tobacco Action Committee 8:00 a.m. - 4:00 p.m. KBHCCD Room C146 (Level 1) Target Audience Providers who take care of patients with lung cancer including pulmonologists, interventional pulmonologists and radiologists, medical and radiation oncologists, fellows-in-training, thoracic surgeons, and physician extenders Objectives At the conclusion of this session, the participant will be able to: • learn how to access and implement web-based resources for lung cancer risk assessment and pulmonary nodule evaluation. Optimize utilization of procedure(s) for lung cancer diagnosis, staging and tissue procurement; • apply the new 8th Edition of the TNM Classification for Lung Cancer including the approach to multiple lesions and differentiating between separate primaries and multifocal adenocarcinoma; • improve and update knowledge of new lung cancer treatments and adverse cardiopulmonary complications associated with new therapies. Apply this knowledge to enhancing diagnostic interventions that will support personalized lung cancer treatment. This comprehensive up-to-date course, coupled with interactive tumor boards, will review the advances in the development of more effective methods for detection, diagnosis and treatment of lung cancer. Tobacco treatment strategies, patient selection and implementation of lung cancer screening, the 8th edition of the TNM staging system, application of biomarkers in clinical practice, new diagnostic and therapeutic bronchoscopic interventions, new surgical and non-surgical strategies for Stage I NSCLC, advances in the role of immunotherapy across all types and stages of lung cancer, management of oligometastatic disease and recognition and management of toxicities due to immunotherapy will be reviewed. Chairing: M.P. Rivera, MD, ATSF, Chapel Hill, NC D.J. Feller-Kopman, MD, Baltimore, MD L.T. Tanoue, MD, New Haven, CT 8:00 Introduction M.P. Rivera, MD, ATSF, Chapel Hill, NC ATS 2019 • Dallas, TX 10 FRIDAY • MAY 17